Prescribing of Contraindicated Protease Inhibitor and Statin Combinations Among HIV-Infected Persons
暂无分享,去创建一个
W. Ray | T. Sterling | T. Hulgan | P. Arbogast | S. Raffanti | J. Daugherty | J. Daugherty
[1] H. Morgenstern,et al. Lipid Screening in HIV-Infected Veterans , 2004, Journal of acquired immune deficiency syndromes.
[2] D. Costagliola,et al. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men , 2003, AIDS.
[3] Rodolphe Thiébaut,et al. Combination antiretroviral therapy and the risk of myocardial infarction , 2003 .
[4] W. K. Henry,et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[5] J. Bailey,et al. Improvements in access to care for HIV and AIDS in a statewide Medicaid managed care system. , 2003, American Journal of Managed Care.
[6] U. Iloeje,et al. Increased use of lipid-lowering therapy in patients receiving human immunodeficiency virus protease inhibitors. , 2003, The American journal of cardiology.
[7] D. Haas,et al. Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy: a randomized comparative pilot trial , 2003, AIDS.
[8] M. Gill,et al. Drug-induced rhabdomyolysis after concomitant use of clarithromycin, atorvastatin, and lopinavir/ritonavir in a patient with HIV. , 2003, AIDS patient care and STDs.
[9] Leonardo Calza,et al. Statins and fibrates for the treatment of hyperlipidaemia in HIV-infected patients receiving HAART , 2003, AIDS.
[10] K. Squires,et al. Results of a Phase 2 Clinical Trial at 48 Weeks (AI424-007): A Dose-Ranging, Safety, and Efficacy Comparative Trial of Atazanavir at Three Doses in Combination with Didanosine and Stavudine in Antiretroviral-Naive Subjects , 2003, Journal of acquired immune deficiency syndromes.
[11] C. B. Hare,et al. Simvastatin-nelfinavir interaction implicated in rhabdomyolysis and death. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[12] Amalio Telenti,et al. Efficacy and safety of fluvastatin in hyperlipidemic protease inhibitor-treated HIV-infected patients. , 2002, AIDS.
[13] M. Schambelan,et al. Management of Metabolic Complications Associated With Antiretroviral Therapy for HIV‐1 Infection: Recommendations of an International AIDS Society‐USA Panel , 2002, Journal of acquired immune deficiency syndromes.
[14] B. Gazzard,et al. Pravastatin does not alter protease inhibitor exposure or virologic efficacy during a 24-week period of therapy. , 2002, Journal of acquired immune deficiency syndromes.
[15] Christine Miller,et al. Rhabdomyolysis due to probable interaction between simvastatin and ritonavir. , 2002, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[16] C. Fichtenbaum,et al. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047 , 2002, AIDS.
[17] M. Murty,et al. Statins: rhabdomyolysis and myopathy. , 2002, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[18] P. Hsyu,et al. Pharmacokinetic Interactions between Nelfinavir and 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Atorvastatin and Simvastatin , 2001, Antimicrobial Agents and Chemotherapy.
[19] J. Fellay,et al. For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .
[20] James P. Wilson,et al. Rhabdomyolysis and HMG-CoA Reductase Inhibitors , 2001, The Annals of pharmacotherapy.
[21] R. Leavitt,et al. Indinavir did not increase the short-term risk of adverse cardiovascular events relative to nucleoside reverse transcriptase inhibitor therapy in four phase III clinical trials. , 2001, AIDS.
[22] A. Telenti,et al. Premature atherosclerosis in HIV-infected individuals – focus on protease inhibitor therapy , 2001, AIDS.
[23] W. K. Henry,et al. Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: Recommendations of the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[24] S. Staszewski,et al. Incidence of myocardial infarctions in HIV-infected patients between 1983 and 1998: the Frankfurt HIV-cohort study. , 2000, European journal of medical research.
[25] A Ammassari,et al. Efficacy and tolerability of pravastatin for the treatment of HIV-1 protease inhibitor-associated hyperlipidaemia: a pilot study. , 2000, AIDS.
[26] S. Hammer,et al. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study. , 2000, Archives of internal medicine.
[27] D. Singer,et al. Understanding physician adherence with a pneumonia practice guideline: effects of patient, system, and physician factors. , 2000, Archives of internal medicine.
[28] M. Cabana,et al. Why don't physicians follow clinical practice guidelines? A framework for improvement. , 1999, JAMA.
[29] K. Henry,et al. Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities , 1998, The Lancet.
[30] P. Kissinger,et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. , 1998, The New England journal of medicine.
[31] G. Satten,et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.
[32] D A Savitz,et al. Recall accuracy for prescription medications: self-report compared with database information. , 1995, American journal of epidemiology.
[33] W. Applegate,et al. TennCare--health system reform for Tennessee. , 1995, JAMA.
[34] R E Johnson,et al. Comparing Sources of Drug Data about the Elderly , 1991, Journal of the American Geriatrics Society.
[35] W A Ray,et al. Use of Medicaid data for pharmacoepidemiology. , 1989, American journal of epidemiology.
[36] W. A. Edwards,et al. A Comparison of Patient Drug Regimens as Viewed by the Physician, Pharmacist and Patient , 1981, Medical care.
[37] B. Strom,et al. Use of automated databases for pharmacoepidemiology research. , 1990, Epidemiologic reviews.